Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery

Emerald Health Therapeutics (TSXV:EMH; OTCQX:EMHTF) announced members of its scientific advisory team made a discovery showing the potential of tetrahydrocannabinolic acid to treat Huntington’s disease and other metabolic, neurodegenerative and neuroinflammatory diseases.
As quoted in the press release:

These results were published in the British Journal of Pharmacology in a peer-reviewed article entitled, “Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.”

This recent article in the British Journal of Pharmacology focused on the activity of Δ9-THCA, one of the most common cannabinoids (and a non-psychotropic precursor of THC), on PPARγ. PPARγ signalling has a role in neuroinflammation and epilepsy. Δ9-THCA is a potent PPARγ agonist and in this study exhibited neuroprotective and anti-neuroinflammatory activity in an animal model of Huntington´s disease.

This research was conducted at Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC). Co-authors of this paper included EHT scientific advisory board members Eduardo Muñoz, MD, PhD, Professor of Immunology at University of Córdoba; Giovanni Appendino, PhD, Professor of Pharmaceutical Chemistry at University of Eastern Piedmont; and Gaetano Morello, ND, clinician, Complex Chronic Disease Program, BC Women’s Hospital.

Click here to read the full press release.

Source: globenewswire.com